Send to

Choose Destination
Gene Ther. 1997 Dec;4(12):1289-99.

Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.

Author information

Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC, USA.


We have redesigned cationic liposomes by using a combination of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol to enhance the in vitro and in vivo effectiveness of antisense raf oligodeoxyribonucleotide (ODN). Circulating ODNs carried in vivo by liposomes were intact for at least 24 h, while free ODNs were undetectable after 5 min. Liposome-encapsulated antisense raf ODN (LE-ATG-AS) inhibited Raf-1 protein expression in vitro and in vivo. Furthermore, radioresistant tumor cells treated with LE-ATG-AS raf ODN were sensitized to ionizing radiation. These data provide new information for the delivery and potency of antisense ODN in vivo, and support the use of LE-ATG-AS raf ODN for gene therapy of radioresistant cancer.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center